68ga-dota-peptides versus 18f-dopa pet for the assessment of net patients

Nuclear Medicine Communications

Volumn 29, Issue 5, 2008, Pages 415-417

  Ambrosini, Valentina ^a   Rubello, Domenico ^a   Nanni, Cristina ^a   Al Nahhas, Adil ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 IODOBENZYLGUANIDINE I 123; CARBIDOPA; DOPAMINE; DOTA NOC GA 68; DOTA TATE LU 177; DOTA TATE Y 90; DOTA TOC GA 68; DOTA TOC Y 90; FLUORODEOXYGLUCOSE F 18; FLUORODOPA F 18; PENTETATE INDIUM IN 111; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

APUD CELL; BONE LEVEL; CELL METABOLISM; CELL SURFACE; COMPUTER ASSISTED TOMOGRAPHY; CYCLOTRON; DECARBOXYLATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DOSIMETRY; DRUG BIOAVAILABILITY; ECHOGRAPHY; EDITORIAL; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; HORMONE RELEASE; HUMAN; ISOTOPE LABELING; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PARAGANGLIOMA; PARKINSON DISEASE; PATIENT ASSESSMENT; PATIENT CARE; PEPTIDE SYNTHESIS; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SCINTIGRAPHY; SECRETORY GRANULE; TREATMENT RESPONSE; TUMOR CELL;

DIHYDROXYPHENYLALANINE; HUMANS; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 41949135884     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282ffd70d     Document Type: Editorial

References (30)

1. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128:1717-1751.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13舁715 carcinoid tumors. Cancer 2003; 97:934-959.
3. Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, Faivre J. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004; 53:549-553.
4. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004; 80 (Suppl 1):3-7.
5. Ueberberg B, Tourne H, Redman A, Walz MK, Schmid KW, Mann K, et al. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 2005; 37:722-728.
6. Papotti M, Kuma U, Volante M, Pecchiono C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol 2001; 54:641-649.
7. Oda Y, Tanaka Y, Naruse T, Sasanabe R, Tsubamoto M, Funahashi H. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today 2002; 32:690-694.
8. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1-5 in81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440:461-475.
9. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21:69-85.
10. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 (Suppl 4):iv1-iv16.
11. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25:79-83.
12. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64:314-319.
13. Otonkoski T, Näntö-Salonen K, Seppänen M, Veijola R, Huopio H, Hussain K, et al. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes 2006; 55:13-18.
14. Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006; 7:728-734.
15. Becherer A, Szabó M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 2004; 45:1161-1167.
16. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001; 220:373-380.
17. Ambrosini V, Tomassetti P, Rubello D, Campana D, Nanni C, Castellucci P, et al. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. Nucl Med Commun 2007; 28:473-477.
18. Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, et al. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 2007; 48:1599-1606.
19. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007; 48:1741-1748.
20. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. (68)Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2007; [Epub ahead of print].
21. Meyer GJ, Macke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004; 31:1097-1104.
22. Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005; 32:724.
23. Antunes P, Ginj M, Zhang H, Naser B, Baum RP, Raubi JC, Maecke H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007; 34:982-993.
24. Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003; 30:1338-1347.
25. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48:508-518.
26. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34:1617-1626.
27. Baum RP, Wehrman C, Zachert C, Mundscheuk J, Prasad V, Wormann R, Morsch D. 5-year follow-up of peptide receptor radionuclide therapy (PRRT) in 379 patients with progressive somatostatin receptor positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34 (Suppl 2):s220.
28. Von Falck C, Boerner AR, Galanski M, Knapp WH. Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation. Eur J Nucl Med Mol Imaging 2007; 34:812.
29. Singh A, Hart JL, Khan S, Szyszko T, Pillay N, Nijran KS, Al-Nahhas A. Clinical significance of adrenal uptake with 68Ga-DOTA-ocreotate PET imaging. J Nucl Med Mol Imaging 2007; 34 (Suppl 2):s192.
30. Mackenzie IS, Gurnell M, Balan KK, Simpson H, Chatterjee K, Brown MJ. The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol 2007; 157:533-537.